|
|
Clinical effect of Thymosin Injection combined with Azithromycin treating the secondary pulmonary infection of chronic obstructive pulmonary disease in the elderly |
XIA Kou-ping1 ZHOU Ying-yong2▲ |
1.Department of Internal Medicine,Yongxiu Traditional Chinese Medicine Hospital of Jiujiang City in Jiangxi Province, Yongxiu 330304,China;
2.Department of Internal Medicine,Yongxiu People′s Hospital of Jiujiang City in Jiangxi Province,Yongxiu 330304,China |
|
|
Abstract ObjectiveTo evaluate the clinical effect of Thymopeptide Enteric Injection combined with Azithromycin treating the secondary pulmonary infection of chronic obstructive pulmonary disease in the elderly.MethodsFrom June 2016 to February 2017,data of 80 patients with the secondary pulmonary infection of chronic obstructive pulmonary disease were selected and counted and analyzed.All the patients were divided into the Azithromycin group and combined treatment group by the random number table method,and there were 40 cases in each group.Azithromycin group was given Azithromycin treatment,and the combined treatment group was treated with Thymopeptide Enteric Injection on the basis of Azithromycin group.The treatment effect,blood gas analysis index improvement,pulmonary function improvement,adverse drug reaction rate and cure time were compared between the two groups.ResultsTreatment effect, blood gas analysis indicators improvement,pulmonary function improvement were better than Azithromycin group(P<0.05). The incidence rate of adverse drug reactions in combined treatment group was lower than that of Azithromycin group (P<0.05).Cure time of combined therapy group was shorter than that of the Azithromycin group (P<0.05).Conclusion Treatment effect of Thymopeptide Enteric Injection combined with Azithromycin in treating the secondary pulmonary infection of chronic obstructive pulmonary disease in the elderly is prominent,and the improvement of blood gas analysis and lung function indicators are better,and the cure time is short,adverse drug is few.It is worthy of clinical reference.
|
|
|
|
|
[1] |
曹玉华,王亦军,成炜,等.小剂量阿奇霉素联合噻托溴铵粉吸入剂治疗稳定期COPD临床可行性分析及对炎症细胞因子的影响[J].国际呼吸杂志,2016,36(21):1601-1605.
|
[2] |
李允,李硕,罗裕文,等.N-乙酰半胱氨酸联合阿奇霉素对慢性阻塞性肺疾病模型大鼠氧化应激的影响[J].中国病理生理杂志,2016,32(5):798-803.
|
[3] |
韩利,张筠,张铁栓,等.长期小剂量阿奇霉素联合布地奈德/福莫特罗治疗Ⅲ、Ⅳ级COPD稳定期患者的疗效[J].实用医学杂志,2016,32(17):2918-2920.
|
[4] |
张媚霞,孙志芬,曲桂红,等.小剂量阿奇霉素联合噻托溴铵治疗老年慢性阻塞性肺疾病的临床疗效观察[J].实用心脑肺血管病杂志,2016,24(7):111-113.
|
[5] |
莫建明.哌拉西林钠舒巴坦钠联合阿奇霉素治疗慢性阻塞性肺疾病急性加重的临床观察[J].临床肺科杂志,2016,21(7):1198-1200.
|
[6] |
刘旭东,吴俊丽,刘云,等.辛伐他汀联合阿奇霉素治疗老年慢性阻塞性肺疾病合并肺动脉高压患者的疗效[J].实用医学杂志,2016,32(7):1199-1200.
|
[7] |
马峰,朱卫华.小剂量大环内酯类药物联合辛伐他汀治疗慢性阻塞性肺疾病合并肺动脉高压疗效评价[J].医学综述,2016,22(1):170-172.
|
[8] |
徐亚静.老年慢性阻塞性肺疾病患者肺部感染病原菌耐药性分析[J].当代医学,2016,22(30):153-154.
|
[9] |
李敏,兰风金,张金焕,等.整体护理辅助阿奇霉素对慢性阻塞性肺疾病的临床效果观察[J].国际护理学杂志,2016,35(24):3449-3451.
|
[10] |
李涛,刘向群,刘景双,等.小剂量阿奇霉素对稳定期老年慢性阻塞性肺疾病患者外周血内TNF-α、IL-8、CRP水平及肺功能的影响[J].中国药物警戒,2016,13(8):460-463.
|
[11] |
王海娟,吴涛,田桂珍,等.胸腺肽联合阿奇霉素治疗老年COPD继发肺部感染疗效及对肺功能和血气指标的影响[J].疑难病杂志,2016,15(3):225-228.
|
[12] |
王印华,王宝华,唐明贵,等.胸腺肽α1在慢性阻塞性肺疾病合并侵袭性肺曲霉菌病中的疗效观察[J].华中科技大学学报(医学版),2014,43(3):348-350.
|
[13] |
林秀娟,田育红,徐宝仪,等.胸腺肽α1治疗老年COPD急性加重期患者疗效及对T淋巴细胞亚群的影响[J].现代中西医结合杂志,2014,(16):1764-1765.
|
[14] |
易涛平,兰四友,陈波,等.老年COPD合并侵袭性肺曲霉菌病的临床特点及伏立康唑与胸腺肽α1联合干预效果分析[J].国际呼吸杂志,2016,36(6):427-430.
|
[15] |
谢星.胸腺肽α1对慢性阻塞性肺疾病急性加重期患者细胞免疫及体液免疫功能的影响[J].临床肺科杂志,2016,21(6):1031-1034.
|
[16] |
杨声灼,朱光升,白燕群,等.胸腺肽α1在改善慢阻肺并肺曲霉菌病患者预后的作用[J].浙江临床医学,2015,17(5):776-777.
|
|
|
|